Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. It operates through the following segments: Small Molecules, Biologics, Branded Formulations, and Research Services. The Small Molecules segment manufactures spanning statins, immunosuppressants, antifungals, anti-obesity, anti-diabetics, ophthalmologicals, oncologicals, and urologicals etc. The Biologics segment provides Insulins and Analogs, biosimilar Monoclonal Antibodies (MAbs), and recombinant proteins The Branded Formulation segment consists of therapeutic areas of diabetology, oncology, immunology and critical care. The Research Services segment covers Syngene development platforms. The company was founded by Kiran Mazumdar-Shaw on November 29, 1978 and is headquartered in Bangalore, India.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company